The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study

doi:10.1007/s00262-021-03115-y

	The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study
	Wang, Wenxian 1,9; Gu, Xiaodong 1,9; Wang, Liping 8; Pu, Xingxiang 7; Feng, Huijing 6; Xu, Chunwei 5; Lou, Guangyuan 1,9; Shao, Lan 1,9; Xu, Yibing 1,9; Wang, Qian 4
刊名	CANCER IMMUNOLOGY IMMUNOTHERAPY
	2021-11-24
关键词	Non-small cell lung cancer PD-L1 Immune checkpoint inhibitor Immune-related adverse event
ISSN号	0340-7004
DOI	10.1007/s00262-021-03115-y
通讯作者	Song, Zhengbo(zheng_bo_song@163.com)
英文摘要	Patients treated with immune checkpoint inhibitors (ICIs) often experience unique immune-related adverse events (irAEs), and the previous studies demonstrated an association between irAEs and better outcomes in patients with ICI treatment for advanced non-small cell lung cancer (NSCLC). However, the correlation between the occurrence of mild and severe irAEs and prognosis remains unclear. Additionally, little is known regarding the association between the timing of mild and severe irAEs and clinical outcomes. We retrospectively conducted a multicenter study of advanced NSCLC patients treated with ICI monotherapy. Of the 222 patients, 79 patients (35.6%) experienced at least one irAE, and most were of grade 1 or 2 (mild) (26.6%). The most common irAEs were pneumonitis (n = 21, 9.5%) and skin-related adverse reactions (n = 19, 8.6%). The median progression-free survival of all patients treated with ICIs was 3.2 months. Patients experiencing irAEs had a better prognosis than those without such events (6.5 vs. 2.6 months, p = 0.004), and mild irAEs were associated with the best prognosis. The difference in overall survival between mild and severe irAEs was significant (34.3 vs. 17.3 months, p = 0.021). We further analyzed differences between patients with irAEs occurring at 3 or 6 weeks, and found that the earlier the occurrence of mild irAEs, the better the prognosis; however, the opposite was true for severe irAEs. In summary, patients with early occurring mild irAEs showed better clinical outcomes, whereas those with early severe irAEs tended to show poorer clinical outcomes.
资助项目	Zhejiang Chinese Medical Science and Technology Foundation[2021ZQ013] ; Xisike-Hanson Cancer Research Foundation[Y-HS2019-20] ; Basic Discipline Layout Project of Shenzhen City[JCYJ20170818110544730] ; Sanming Project of Medicine in Shenzhen[SZSM 201801060]
WOS关键词	NIVOLUMAB ; ASSOCIATION ; DOCETAXEL ; IPILIMUMAB ; EFFICACY
WOS研究方向	Oncology ; Immunology
语种	英语
出版者	SPRINGER
WOS记录号	WOS:000722115000002
资助机构	Zhejiang Chinese Medical Science and Technology Foundation ; Xisike-Hanson Cancer Research Foundation ; Basic Discipline Layout Project of Shenzhen City ; Sanming Project of Medicine in Shenzhen
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126612]
专题	中国科学院合肥物质科学研究院
通讯作者	Song, Zhengbo
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol, 1 Banshan East St, Hangzhou 310022, Zhejiang, Peoples R China 2.ShenZhen Univ, Dept Oncol, Affiliated Hosp 3, Shenzhen 518001, Guangdong, Peoples R China 3.ShenZhen Univ Hlth Sci Ctr, Shenzhen 518001, Guangdong, Peoples R China 4.Nanjing Univ Chinese Med, Jiangsu Prov Hosp Chinese Med, Dept Resp Med, Affiliated Hosp, Nanjing 210029, Jiangsu, Peoples R China 5.Nanjing Univ, Jinling Hosp, Dept Resp Med, Sch Med, Nanjing 210002, Jiangsu, Peoples R China 6.Shanxi Acad Med Sci, Shanxi Bethune Hosp, Dept Thorac Oncol, Taiyuan 030032, Shanxi, Peoples R China 7.Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med,Dept Med Oncol, Changsha 410013, Hunan, Peoples R China 8.Baotou Canc Hosp, Dept Oncol, Baotou 014000, Inner Mongolia, Peoples R China 9.Chinese Acad Sci, Inst Basic Med & Canc IBMC, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Wang, Wenxian,Gu, Xiaodong,Wang, Liping,et al. The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY,2021.
APA	Wang, Wenxian.,Gu, Xiaodong.,Wang, Liping.,Pu, Xingxiang.,Feng, Huijing.,...&Song, Zhengbo.(2021).The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study.CANCER IMMUNOLOGY IMMUNOTHERAPY.
MLA	Wang, Wenxian,et al."The prognostic impact of mild and severe immune-related adverse events in non-small cell lung cancer treated with immune checkpoint inhibitors: a multicenter retrospective study".CANCER IMMUNOLOGY IMMUNOTHERAPY (2021).